Amylyx to withdraw ALS therapy Relyvrio in US, Canada

04 Apr 2024
firstwordpharma.com
Phase 2Phase 3OligonucleotideDrug Approval
Amylyx Pharmaceuticals will withdraw Relyvrio (sodium phenylbutyrate/taurursodiol) from the US market, following through on a commitment made when the amyotrophic lateral sclerosis (ALS) therapy controversially won accelerated approval in 2022. At that time, joint CEO Justin Klee said such a move would be likely if a confirmatory study failed – the company announced last month that the PHOENIX trial was a dud.
Klee, along with joint CEO Joshua Cohen, said Thursday that the decision to withdraw Relyvrio was “reached…in partnership with the stakeholders who will be impacted.” Amylyx, which will also pull the drug in Canada, where it is sold as Albrioza, noted that it will provide the therapy free of charge for those currently on treatment who want to continue.
Staff losses of 70%
The drugmaker will also cut around 70% of its workforce as part of a restructuring plan as it looks to prioritise resources, extending its cash runway into 2026. Amylyx is also investigating the oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol - known as AMX0035 - in Wolfram syndrome and progressive supranuclear palsy (PSP). Interim data from the Phase II HELIOS trial of AMX0035 for the treatment of Wolfram syndrome are expected later this month.
Meanwhile, chief medical officer Camille Bedrosian, noted that the Phase III ORION study of AMX0035 for PSP is ongoing, with “an interim analysis…now expected in mid-2025.” Amylyx has also not given up on ALS, with AMX0114, an antisense oligonucleotide targeting calpain-2, set to enter clinical studies in the second half of the year.
For related analysis, read KOL Views Q&A: Leading neurologist outlines where ALS field goes next after Amylyx’s Relyvrio failure.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.